Loading...

APC/Cyanine7 anti-human CD45 Antibody

Pricing & Availability
Clone
HI30 (See other available formats)
Regulatory Status
RUO
Workshop
IV N816
Other Names
LCA, T200
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HI30_APCCyanine7_CD45_Antibody_031919_updated.png
Human peripheral blood lymphocytes stained with CD45 (clone HI30) APC/Cyanine7 (filled histogram) or Mouse IgG1, κ isotype control (open histogram)
  • HI30_APCCyanine7_CD45_Antibody_031919_updated.png
    Human peripheral blood lymphocytes stained with CD45 (clone HI30) APC/Cyanine7 (filled histogram) or Mouse IgG1, κ isotype control (open histogram)
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Save
304014 100 tests ¥51,980
Description

CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections9, inhibition of CD45 functions4, immunofluorescence11, Western blotting3, and spatial biology (IBEX)16,17.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Kishihara K, et al. 1993. Cell 74:143.
  3. Esser M, et al. 2001. J. Virol. 75:6173. (WB)
  4. Yamada T, et al. 2002. J. Biol. Chem. 277:28830.
  5. Nagano M, et al. 2007. Blood 110:151.
  6. Jiang Q, et al. 2008. Blood 112:2858. PubMed
  7. Morozov A, et al. 2010. Clin Cancer Res. 16:5630. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  10. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
  11. Rees LE, et al. 2003. Clin. Exp. Immunol. 134:497. (IF)
  12. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
  13. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
  14. Marquardt N, et al. 2015. J Immunol. 6:2467. PubMed
  15. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110. (IF) PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Li M, et al. 2021. J Clin Invest. 131:. PubMed
  2. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  3. Qin L, et al. 2022. Sci Adv. 8:eabn3774. PubMed
  4. Suresh V, et al. 2022. FASEB J. 36:e22449. PubMed
  5. McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed
  6. Basil MC, et al. 2022. Nature. 604:120. PubMed
  7. Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed
  8. Veatch JR, et al. 2022. Cancer Cell. 40:393. PubMed
  9. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  10. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
  11. Shen WY, et al. 2023. iScience. 26:106805. PubMed
  12. Chen Z, et al. 2023. Nat Commun. 14:3469. PubMed
  13. Zong D, et al. 2021. BMC Biol. 19:79. PubMed
  14. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  15. Ryzhov S, et al. 2019. J Am Heart Assoc. 8:e010874. PubMed
  16. Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed
  17. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  18. Zhao Y, et al. 2021. Front Immunol. 12:665442. PubMed
  19. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  20. Aghajani Nargesi A, et al. 2019. Stem Cell Rev Rep. 0.921527778. PubMed
  21. Thomas A, et al. 2021. Cancer Cell. 39(4):566-579.e7. PubMed
  22. V Faivre, A Lukaszewicz, D Payen 2016. PLoS One. 11:e0164489. PubMed
  23. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
  24. Kathiriya JJ, et al. 2022. Nat Cell Biol. 24:10. PubMed
  25. Ma L, et al. 2021. Clinical Cancer Research. 27(6):1778-1791. PubMed
  26. Noel S, et al. 2015. J Am Soc Nephrol. 101681/ASN2014100978. PubMed
  27. Blatt K, et al. 2014. Clin Cancer Res. 20:3589. PubMed
  28. Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed
  29. Xu L, et al. 2022. Front Oncol. 12:967982. PubMed
  30. Rochman M, et al. 2022. JCI Insight. 7:. PubMed
  31. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  32. Yin W, et al. 2021. Thorac Cancer. 12:2680. PubMed
  33. Hornburg M, et al. 2021. Cancer Cell. . PubMed
  34. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  35. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  36. Holstein M, et al. 2018. Mol Ther. 26:1137. PubMed
  37. Ugawa M, et al. 2021. Elife. 10:. PubMed
  38. Yuan Z, et al. 2018. Emerg Microbes Infect. 7:59. PubMed
  39. Pearson JM, et al. 2020. Molecular Cancer Research. 18(3):352-363. PubMed
  40. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  41. Leone D, et al. 2016. PLoS One. 11: 0151674. PubMed
  42. Singh N, et al. 2017. J Endocrinol. 235:69. PubMed
  43. Tripathi H, et al. 2020. Stem Cell Rev Rep. 0.953472222. PubMed
  44. Li G, et al. 2019. J Virol. 93:e00233-19. PubMed
  45. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  46. Worthen CA, et al. 2020. J Invest Dermatol. 140:2515. PubMed
  47. Wei C, et al. 2016. Cell Death Dis. 7:e2489. PubMed
  48. Wang L, et al. 2014. Proc Natl Acad Sci U S A. 111:3146. PubMed
  49. Annageldiyev C, et al. 2019. Haematologica. 10.3324/haematol.2018.212886. PubMed
  50. Mori A, et al. 2021. Cells. :10. PubMed
  51. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  52. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  53. Le J, et al. 2020. Immunity. 52(6):1105-1118.e9. PubMed
  54. Diaz M, et al. 2017. Stem Cells. 10.1002/stem.2587. PubMed
  55. Novak R, et al. 2022. Cell Death Dis. 13:820. PubMed
  56. Duinhouwer L, et al. 2015. PLoS One. 10:119086. PubMed
  57. Meziane O, et al. 2020. J Virol. 94:00:00. PubMed
  58. Mesa-Nuñez C, et al. 2020. Stem Cell Res Ther. 11:164. PubMed
  59. Pham TNQ, et al. 2020. Cell Reports. 29(9):2770-2782.e5.. PubMed
  60. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  61. Cai T, et al. 2022. Nat Commun. 13:2228. PubMed
  62. Mesa-Nuñez C, et al. 2022. Mol Ther Methods Clin Dev. 26:459. PubMed
  63. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  64. Crinier A, et al. 2018. Immunity. 49:971. PubMed
  65. Román-Rodriguez FJ, et al. 2019. Cell Stem Cell. 25:607. PubMed
  66. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  67. Tomita T, et al. 2021. Nat Commun. 12:3655. PubMed
  68. Bharat A, et al. 2020. Science Translational Medicine. 12(574):. PubMed
  69. Yang Z, et al. 2022. Transl Androl Urol. 11:803. PubMed
  70. Alhaj Hussen K, et al. 2020. Front Immunol. 11:579776. PubMed
  71. Wu X, et al. 2022. Front Immunol. 13:849493. PubMed
  72. Medeiros-Furquim T, et al. 2022. Front Immunol. 13:678817. PubMed
RRID
AB_314402 (BioLegend Cat. No. 304014)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane protein, 180-240 kD (multiple isoforms)
Distribution

Hematopoietic cells, not expressed in circulating erythrocytes or platelets

Function
TCR and BCR mediated activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
Hematopoietic stem and progenitors, Mesenchymal Stem Cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References
  1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
  2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.
Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD45 HI30 FC
Biotin anti-human CD45 HI30 FC
FITC anti-human CD45 HI30 FC
PE anti-human CD45 HI30 FC
PE/Cyanine5 anti-human CD45 HI30 FC
Purified anti-human CD45 HI30 FC,CyTOF®,IHC-P,WB,IHC-F,ICC
APC/Cyanine7 anti-human CD45 HI30 FC
PE/Cyanine7 anti-human CD45 HI30 FC
Alexa Fluor® 488 anti-human CD45 HI30 FC
Alexa Fluor® 647 anti-human CD45 HI30 FC
Pacific Blue™ anti-human CD45 HI30 FC
Alexa Fluor® 700 anti-human CD45 HI30 FC
PerCP anti-human CD45 HI30 FC
PerCP/Cyanine5.5 anti-human CD45 HI30 FC,SB
Brilliant Violet 421™ anti-human CD45 HI30 FC
Brilliant Violet 570™ anti-human CD45 HI30 FC
Brilliant Violet 510™ anti-human CD45 HI30 FC
Brilliant Violet 605™ anti-human CD45 HI30 FC
Brilliant Violet 650™ anti-human CD45 HI30 FC
Purified anti-human CD45 (Maxpar® Ready) HI30 FC,CyTOF®
Brilliant Violet 785™ anti-human CD45 HI30 FC
Brilliant Violet 711™ anti-human CD45 HI30 FC
PE/Dazzle™ 594 anti-human CD45 HI30 FC
Alexa Fluor® 594 anti-human CD45 HI30 IHC-P,SB
APC/Fire™ 750 anti-human CD45 HI30 FC
Pacific Blue™ anti-human CD45 HI30 FC
APC anti-human CD45 HI30 FC
PE/Cyanine7 anti-human CD45 HI30 FC
PE/Dazzle™ 594 anti-human CD45 HI30 FC
TotalSeq™-A0391 anti-human CD45 HI30 PG
TotalSeq™-B0391 anti-human CD45 HI30 PG
TotalSeq™-C0391 anti-human CD45 HI30 PG
PerCP/Cyanine5.5 anti-human CD45 HI30 FC
APC/Fire™ 750 anti-human CD45 HI30 FC
PE/Fire™ 640 anti-human CD45 HI30 FC
APC/Fire™ 810 anti-human CD45 HI30 FC
Spark YG™ 570 anti-human CD45 HI30 IHC-P
PE/Fire™ 700 anti-human CD45 HI30 FC
FITC anti-human CD45 HI30 FC
PerCP anti-human CD45 HI30 FC
Alexa Fluor® 660 anti-human CD45 Antibody HI30 FC
Spark Violet™ 538 anti-human CD45 HI30 FC
Spark YG™ 593 anti-human CD45 HI30 FC
GMP APC/Fire™ 750 anti-human CD45 HI30 FC
Spark Violet™ 538 anti-human CD45 HI30 FC
GMP APC anti-human CD45 HI30 FC
Spark UV™ 387 anti-human CD45 HI30 FC
GMP Pacific Blue™ anti-human CD45 HI30 FC
GMP PerCP anti-human CD45 HI30 FC
GMP FITC anti-human CD45 HI30 FC
PE anti-human CD45 HI30 FC
GMP PE/Dazzle™ 594 anti-human CD45 HI30 FC
GMP PerCP/Cyanine5.5 anti-human CD45 HI30 FC
Spark Blue™ 515 anti-human CD45 HI30 FC
TotalSeq™-D0391 anti-human CD45 HI30 PG
GMP PE/Cyanine7 anti-human CD45 HI30 FC
Spark Violet™ 500 anti-human CD45 HI30 FC
GMP PE anti-human CD45 HI30 FC
PE/Fire™ 810 anti-human CD45 HI30 FC
Spark PLUS UV395™ anti-human CD45 HI30 FC
Spark NIR™ 685 anti-human CD45 HI30 FC
Spark Violet™ 423 anti-human CD45 HI30 FC

Customers Also Purchased

FITC anti-human CD45
Clone: HI30

PE anti-human CD45
Clone: HI30

APC anti-human CD45
Clone: HI30

APC anti-human CD19
Clone: HIB19

Go To Top Version: 3    Revision Date: 03/19/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account